Pfizer withdraws Premarin menopause therapy in Canada

Pfizer is discontinuing Premarin hormone therapy in Canada after an internal review, ending supply of the vaginal cream, which has been in shortage since June, and stopping sales of the tablets. Existing tablet inventories in three strengths are expected to last until around mid-2027, though they could run out earlier if demand rises. Pfizer said the decision was not driven by safety, efficacy or quality concerns and that other treatments are available. The withdrawal comes as demand for hormone therapy increases and some estradiol patches are also in short supply in Canada, potentially tightening access to menopause treatments.